Phase 2 Study of Maintenance OSI-906 Plus Erlotinib (Tarceva®), or Placebo Plus Erlotinib in Patients With Nonprogression Following 4 Cycles of Platinum-based Chemotherapy

NCT01186861 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

205

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Small Cell Lung Cancer (NSCLC) With Nonprogression Following 4 Cycles of Platinum-based Chemotherapy

Interventions

DRUG: OSI-906
DRUG: erlotinib
DRUG: placebo

Sponsor

Astellas Pharma Inc